Literature DB >> 1372591

The effect of neonatal tolerance to bovine gamma globulin (BGG) on BGG-reactive CD4+ T lymphocytes.

S S Burtles1, D C Hooper.   

Abstract

Compelling evidence has been presented that tolerance to major histocompatibility complex (MHC) and other antigens expressed on cells of the thymus is due to clonal deletion. However, it has not been determined conclusively how tolerance to diverse antigens, which may initially interact with the immune system in the periphery, is induced and maintained. Considerable evidence exists to suggest that mechanisms other than deletion, such as clonal anergy or immunoregulation, may be involved. We have previously shown that the clonal deletion of CD4+ cells specific for bovine gamma globulin (BGG) does not occur during induction of tolerance to this soluble antigen in adult life. In this study we have extended our previous findings by examining unresponsiveness to BGG which had been established during early ontogeny, when natural tolerance of self-antigens is likely to develop. It is demonstrated here that BGG-reactive, CD4+8- T cells, which proliferate and secrete interleukin-2 on stimulation with BGG in vitro, can be obtained from mice rendered tolerant of BGG as neonates. Even though the mice from which they were derived were unable to respond to BGG, these BGG-reactive T cells, by the parameters tested here, could not readily be distinguished from the corresponding cells in BGG-immune and non-immune animals. It is therefore evident that this tolerant state is not simply the result of clonal deletion of BGG-reactive CD4+ T cells but is more likely to be due to a reversible mechanism which controls their responsiveness in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372591      PMCID: PMC1384712     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  19 in total

1.  Actively acquired tolerance of foreign cells.

Authors:  R E BILLINGHAM; L BRENT; P B MEDAWAR
Journal:  Nature       Date:  1953-10-03       Impact factor: 49.962

2.  Neonatal T-cell tolerance to minimal immunogenic peptides is caused by clonal inactivation.

Authors:  G Gammon; K Dunn; N Shastri; A Oki; S Wilbur; E E Sercarz
Journal:  Nature       Date:  1986 Jan 30-Feb 5       Impact factor: 49.962

3.  An analysis of T-cell receptor variable region gene expression in major histocompatibility complex disparate mice.

Authors:  J Bill; V B Appel; E Palmer
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

4.  T cell immunity or tolerance as a consequence of self antigen presentation.

Authors:  R H Lin; B Stockinger
Journal:  Eur J Immunol       Date:  1989-01       Impact factor: 5.532

Review 5.  T cell-dependent suppression of an anti-hapten antibody response.

Authors:  A Basten; J F Miller; P Johnson
Journal:  Transplant Rev       Date:  1975

6.  Bovine gamma globulin-specific CD4+ T cells are retained by bovine gamma-globulin-tolerant mice.

Authors:  S S Burtles; R B Taylor; D C Hooper
Journal:  Eur J Immunol       Date:  1990-06       Impact factor: 5.532

7.  Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes.

Authors:  P Kisielow; H Blüthmann; U D Staerz; M Steinmetz; H von Boehmer
Journal:  Nature       Date:  1988-06-23       Impact factor: 49.962

8.  Direct evidence for functional self-protein/Ia-molecule complexes in vivo.

Authors:  R G Lorenz; P M Allen
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

9.  Lymphocyte infiltration into cerebellum in transgenic mice carrying human IL-2 gene.

Authors:  M Katsuki; M Kimura; M Ohta; H Otani; O Tanaka; T Yamamoto; S Nozawa-Kimura; M Yokoyama; T Nomura; S Habu
Journal:  Int Immunol       Date:  1989       Impact factor: 4.823

10.  A natural model of immunologic tolerance. Tolerance to murine C5 is mediated by T cells, and antigen is required to maintain unresponsiveness.

Authors:  D E Harris; L Cairns; F S Rosen; Y Borel
Journal:  J Exp Med       Date:  1982-08-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.